NanoVibronix stockholders approve reverse stock split (1:2 to 1:11) and warrant issuance at special meeting

ENvue Medical, Inc.

Reverse stock split approved: 1,560,759 for, 674,302 against; board may set ratio between 1-for-2 and 1-for-11.
Issuance of shares underlying warrants from Jan 7 Exchange Agreement approved: 417,111 for, 290,431 against, with 1,528,273 broker non-votes.
Adjournment proposal approved but not needed as sufficient votes existed for both proposals.
Record date Jan 17, 2025; 6,138,028 shares outstanding; 2,242,618 votes present at meeting.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.